gpcr
(3)
Abalone Bio
Abalone Bio is an Emeryville-based preclinical biotech building target-activating antibodies for diseases other drugs can't reach. Its FAST platform pairs engineered yeast cells with AI/ML to screen ~100 million antibodies per experiment for functional activity, not just binding, with an initial focus on G-protein coupled receptors (GPCRs) and metabolic disease.
Multispan, Inc.
Multispan, Inc. is a Hayward, California biotech that builds the cell lines and assays drug hunters use to interrogate G protein-coupled receptors (GPCRs), the largest druggable target family in the human genome. Founded in 2004 by Helena Mancebo, the company has assembled one of the industry's largest libraries of clonally derived, GPCR-expressing stable cell lines - 600+ lines and 2,000+ ready-to-use reagents - and pairs them with custom assay development, compound profiling, antibody work, and CRISPR cell engineering. Its MULTISCREEN platform and proprietary HEx high-expression cell technology let pharmaceutical and academic teams screen, profile, and validate candidate drugs against receptors that are notoriously hard to express and measure.
Nabla Bio
Nabla Bio is a Cambridge, Massachusetts biotech building AI plus wet-lab technology to design antibodies and protein therapeutics from scratch. Its Joint Atomic Modeling (JAM) platform generates de novo binders against historically undruggable membrane proteins like GPCRs, and the company has signed collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth over a billion dollars in potential payments.